Medical Imaging Product Innovation of the Year
Burbank, CA (PRWEB) May 5, 2008
Imaging3™, Inc. (OTCBB: IMGG), developer of a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time, conducted a conference call on April 29, 2008 that summarized the company's progress to date.
The conference call was conducted by Mr. Dean Janes, CEO of Imaging3, and a recording of the call can be found on the company's website Imaging3, Inc..
Mr. Janes reviewed the Company's progress to date on a number of substantive initiatives, including the company being granted FDA Investigative Device Exception (IDE) approval and its relevance as a milestone and step towards full FDA approval. Mr. Janes also discussed the importance of receiving the prestigious "Medical Imaging Product Innovation of the Year" award from Frost & Sullivan and noted the value that this independent validation represents. Before opening the conference call for questions Mr. Janes also reviewed other marketing initiatives as well as an update on the existing C-Arm remanufacturing business.
Imaging3, Inc., founded in 1993, is a leading provider of advanced technology medical imaging devices. The Company has developed a breakthrough medical imaging device that produces 3D medical diagnostic images of virtually any part of the human body in real-time. Because these 3D images are instantly constructed in real-time, they can be used for any current or new medical procedures in which multiple frames of reference are required to perform medical procedures on or in the human body. Visit the company's website at Imaging3, Inc. for more information.
Safe Harbor Statement
Matters discussed in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. When used in this press release, the words "anticipate," "believe," "estimate," "may," "intend," "expect" and similar expressions identify such forward-looking statements. Actual results, performance, or achievements could differ materially from those contemplated, expressed, or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the Company and are subject to a number of risks and uncertainties. These include, but are not limited to, risks and uncertainties associated with: the impact of economic, competitive, and other factors affecting the Company and its operations, markets, product, and distributor performance, the impact on the national and local economies resulting from terrorist actions, and U.S. actions subsequently; and other factors detailed in reports filed by the Company.